Search results for "Amides"

showing 10 items of 552 documents

Synergistic effect between amoxicillin and TLR ligands on dendritic cells from amoxicillin-delayed allergic patients.

2013

Journal Article; Amoxicillin, a low-molecular-weight compound, is able to interact with dendritic cells inducing semi-maturation in vitro. Specific antigens and TLR ligands can synergistically interact with dendritic cells (DC), leading to complete maturation and more efficient T-cell stimulation. The aim of the study was to evaluate the synergistic effect of amoxicillin and the TLR2, 4 and 7/8 agonists (PAM, LPS and R848, respectively) in TLR expression, DC maturation and specific T-cell response in patients with delayed-type hypersensitivity (DTH) reactions to amoxicillin. Monocyte-derived DC from 15 patients with DTH to amoxicillin and 15 controls were cultured with amoxicillin in the pr…

MaleCélulas dendríticasmedicine.medical_treatmentLymphocyte proliferationPharmacology:Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Laboratory Chemicals::Ligands [Medical Subject Headings]Monocytes:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Pharmacological Processes::Drug Interactions::Drug Synergism [Medical Subject Headings]Cells CulturedAmoxicilinaMultidisciplinarymedicine.diagnostic_testChemistryQRLinfocitosImidazolesCitocinasMiddle AgedHumanosCytokineMedicineCytokinesFemaleDrug EruptionsResearch Article:Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Exanthema [Medical Subject Headings]AdultSinergismo medicamentosoScienceFlow cytometryHipersensibilidad retardada:Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Penicillins::Penicillin G::Ampicillin::Amoxicillin [Medical Subject Headings]Immune systemAntigen:Diseases::Immune System Diseases::Hypersensitivity::Hypersensitivity Delayed [Medical Subject Headings]ExantemamedicineHypersensitivity:Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes Mononuclear::Lymphocytes [Medical Subject Headings]HumansLigandos:Chemicals and Drugs::Amino Acids Peptides and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings]:Anatomy::Cells::Antigen-Presenting Cells::Dendritic Cells [Medical Subject Headings]TLR9AmoxicillinTLR7Dendritic CellsToll-Like Receptor 2TLR2ImmunologyPloS one
researchProduct

Genotoxic effects of the herbicides alachlor, atrazine, pendimethaline, and simazine in mammalian cells

1994

MaleHealth Toxicology and MutagenesisSimazineSimazineToxicologyRats Sprague-Dawleychemistry.chemical_compoundAcetamidesAnimalsHumansEcotoxicologyLymphocytesAtrazineCells CulturedAniline CompoundsHerbicidesMutagenicity TestsChemistrybusiness.industryAlachlorGeneral MedicinePesticidePollutionRatsBiotechnologyLiverAtrazinebusinessSister Chromatid ExchangeDNA DamageBulletin of Environmental Contamination and Toxicology
researchProduct

Chronic quercetin feeding decreases plasma concentrations of salicylamide phase II metabolites in pigs following oral administration.

2011

We investigated acute effects and effects after chronic intake of the orally administered flavonol quercetin on pharmacokinetics of salicylamide metabolites (SAM) after oral administration of salicylamide in pigs. Salicylamide (8 mg/kg body weight) was orally administered to seven pigs either without or with quercetin (10 mg/kg body weight). Additionally, salicylamide was administered to five pigs that had received a diet supplemented with the flavonol for 1 week. Daily quercetin intake was 10 mg/kg in these animals. Co-ingestion of quercetin with the drug did not alter area under the concentration-time curve (AUC(0→∞)), time to achieve maximum plasma concentration (t(max)), mean residence …

MaleHealth Toxicology and MutagenesisSus scrofaAdministration OralSalicylamidePharmacologyToxicologyBiochemistryExcretionchemistry.chemical_compoundPharmacokineticsIntestinal mucosaOral administrationSalicylamidesmedicineAnimalsheterocyclic compoundsPharmacologyChemistryGeneral MedicineMetabolismFeeding BehaviorDrug interactionMetabolic Detoxication Phase IIDietQuercetinQuercetinmedicine.drugXenobiotica; the fate of foreign compounds in biological systems
researchProduct

FM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation Status

2009

The biology of the alpha subunits of hypoxia-inducible factors (HIF alpha) has expanded from their role in angiogenesis to their current position in the self-renewal and differentiation of stem cells. The results reported in this article show the discovery of FM19G11, a novel chemical entity that inhibits HIF alpha proteins that repress target genes of the two alpha subunits, in various tumor cell lines as well as in adult and embryonic stem cell models from rodents and humans, respectively. FM19G11 inhibits at nanomolar range the transcriptional and protein expression of Oct4, Sox2, Nanog, and Tgf-alpha undifferentiating factors, in adult rat and human embryonic stem cells, FM19G11 activit…

MaleHomeobox protein NANOGTranscription GeneticCellular differentiationBiologyResponse ElementsBenzoatesBiochemistryHistonesRats Sprague-DawleyMolecular Basis of Cell and Developmental BiologySOX2EpendymaBasic Helix-Loop-Helix Transcription FactorsAnimalsHumansp300-CBP Transcription FactorsMolecular BiologyEmbryonic Stem CellsHomeodomain ProteinsRegulation of gene expressionSOXB1 Transcription FactorsAcetylationCell DifferentiationNanog Homeobox ProteinCell BiologyTransforming Growth Factor alphaHypoxia-Inducible Factor 1 alpha SubunitMolecular biologyEmbryonic stem cellCell HypoxiaRatsCell biologyAdult Stem CellsGene Expression RegulationPharmaceutical PreparationsBenzamidesStem cellOctamer Transcription Factor-3Chromatin immunoprecipitationHeLa CellsAdult stem cellJournal of Biological Chemistry
researchProduct

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

2012

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

MaleIndolesTime FactorsClinical BiochemistryPilot ProjectsPharmacologyBiochemistryGastroenterologychemistry.chemical_compoundFenofibrateRisk FactorsProspective StudiesRosuvastatin CalciumHypolipidemic AgentsSulfonamidesFenofibratebiologyGeneral MedicineMiddle AgedRosuvastatin CalciumC-Reactive ProteinCardiovascular DiseasesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Laropiprantmedicine.drugAdultmedicine.medical_specialtyStatinmedicine.drug_classNiacinInternal medicinemedicineHumansRosuvastatinAgedApolipoproteins BDyslipidemiasbusiness.industryCholesterolC-reactive proteinnutritional and metabolic diseasesCholesterol LDLAtherosclerosismedicine.diseaseFluorobenzenesPyrimidineschemistry1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaEuropean Journal of Clinical Investigation
researchProduct

The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.

2013

Purpose: To describe the study design and baseline factors of the Heidelberg Retina Tomograph ancillary study within the EGPS. Furthermore, to examine the relationship between HRT optic disc topographic measurements and baseline demographic and ocular factors. Methods: Four hundred and eighty-nine ocular hypertensive participants were included. Each participant completed HRT imaging at least annually. The associations between HRT measurements and IOP, central corneal thickness (CCT), baseline photographic estimates of vertical CDR ratio (CDR), asymmetry between the two eyes in CDR ratio and baseline visual field indices were assessed using regression analysis. Results: Associations between …

MaleIntraocular pressureVisual acuitygenetic structuresOptic diskVisual AcuityOcular hypertensionGlaucomaOptic Nerve DiseasesMedicineHRT parameterCarbonic Anhydrase Inhibitorspattern standard deviationTomographySulfonamidesmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.anatomical_structureResearch DesignOptic nerveFemalemedicine.symptomHumanOptic discmedicine.medical_specialtyCarbonic Anhydrase Inhibitorscanning laser ophthalmoscopyOptic DiskVisual FieldThiophenesSulfonamideOphthalmoscopyTonometry OcularOptic Nerve DiseaseDouble-Blind MethodThiopheneOphthalmologymental disordersHumansIntraocular Pressurebusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyOcular Hypertensionsense organsVisual Fieldsbusinesscentral corneal thickneActa ophthalmologica
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct

Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.

2010

To evaluate the efficacy and tolerability of preservative-free eye drops (dorzolamide/timolol) in routine management of preservative-sensitive glaucoma patients.Data from 2,298 glaucoma patients requiring intraocular pressure (IOP) reduction and suffering from intolerance to benzalkonium chloride or active agents of previously used eye drops were valid for baseline and safety analysis in this prospective, open, noncomparative, multicenter, noninterventional study. Patients were treated with preservative-free dorzolamide/timolol eye drops for 12 weeks. Main efficacy endpoint was IOP reduction after 12 weeks of treatment. Two thousand forty-nine patients were considered for efficacy analysis.…

MaleIntraocular pressuregenetic structuresEye diseasemedicine.medical_treatmentAdministration TopicalGlaucomaTimololHyperemiaThiophenesDorzolamideMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAntihypertensive AgentsIntraocular PressureAgedPharmacologySulfonamidesbusiness.industryPreservatives PharmaceuticalEye dropmedicine.diseaseeye diseasesOphthalmologyDrug CombinationsTreatment OutcomeTolerabilityAnesthesiaTimololFemalesense organsOphthalmic SolutionsbusinessBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

A prospective, randomized, triple-blind comparison of articaine and bupivacaine for maxillary infiltrations

2011

Objectives: To compare the clinical anesthetic efficacy of 0.5% bupivacaine and 4% articaine (both with 1:200.000 adrenaline) for anterior maxillary infiltration in healthy volunteers. Material and methods: A triple-blind split-mouth randomized clinical trial was carried out in 20 volunteers. A supraperiosteal buccal injection of 0.9 ml of either solution at the apex of the lateral incisor was done in 2 appointments separated 2 weeks apart. The following outcome variables were measured: latency time, anesthetic efficacy (dental pulp, keratinized gingiva, alveolar mucosa and upper lip mucosa and tissue) and the duration of anesthetic effect. Hemodynamic parameters were monitored during the p…

MaleLocal anesthesiaAnestèsia en odontologiaTime FactorsLidocaineAnesthesia DentalDentistryJawsCarticaineArticaineInjectionsYoung AdultCarticainestomatognathic systemMaxillamedicineHumansProspective StudiesAnesthetics LocalGeneral DentistryAlveolar mucosaBupivacaineMaxil·larsbusiness.industryClinical and Experimental dentistryHemodynamicsLidocaineAnestèsia localBuccal administration:CIENCIAS MÉDICAS [UNESCO]AmidesInjeccionsstomatognathic diseasesOtorhinolaryngologyResearch DesignAnesthesiaMaxillaUNESCO::CIENCIAS MÉDICASAnestheticResearch-ArticleFemaleSurgeryAnesthesia in dentistrybusinessAnesthesia Localmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct